Anebulo Pharmaceuticals, Inc.
ANEB- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001815974
No open-market purchases or sales by Anebulo Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Anebulo Pharmaceuticals, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- −2 vs. Q1 2024
- Shares held
- 7.31M
- +1.43K (0.0%) vs. Q1 2024
- Total value
- $20.0M
- −$1.02M (−4.9%) vs. Q1 2024
- New holders
- 1
- 4 more added
- Sold out
- 3
- 2 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ANEB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 19 | $6.81M |
| Q3 2025 | 21 | $55.5M |
| Q2 2025 | 18 | $32.5M |
| Q1 2025 | 18 | $29.4M |
| Q4 2024 | 15 | $37.3M |
| Q3 2024 | 13 | $14.2M |
| Q2 2024 | 13 | $20.0M |
| Q1 2024 | 15 | $21.0M |
| Q4 2023 | 14 | $17.6M |
| Q3 2023 | 12 | $21.6M |
| Q2 2023 | 12 | $16.5M |
| Q1 2023 | 10 | $19.8M |
| Q4 2022 | 12 | $17.1M |
| Q3 2022 | 11 | $19.2M |
| Q2 2022 | 9 | $24.3M |
| Q1 2022 | 10 | $29.5M |
| Q4 2021 | 10 | $25.8M |
| Q3 2021 | 9 | $27.5M |
| Q2 2021 | 9 | $28.7M |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Anebulo Pharmaceuticals, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| 22NW, LP | 5,366,290 | $14.6M | 12.50% | 00.0% | Unchanged |
| LVW Advisors, LLC | 642,039 | $1.75M | 0.26% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 511,073 | $1.40M | 0.14% | 00.0% | Unchanged |
| Morgan Stanley | 399,219 | $1.09M | 0.00% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 157,862 | $431.0K | 0.13% | 00.0% | Unchanged |
| Vanguard Group Inc | 153,873 | $420.1K | 0.00% | +401+0.3% | Added |
| Geode Capital Management, LLC | 51,308 | $140.1K | 0.00% | +28,531+125.3% | Added |
| Boothbay Fund Management, LLC | 18,978 | $51.8K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 3,761 | $10.3K | 0.00% | −288−7.1% | Reduced |
| Tower Research Capital LLC (TRC) | 3,300 | $9.01K | 0.00% | −1,838−35.8% | Reduced |
| Bank of America Corp | 65 | $177 | 0.00% | +65 | New |
| JPMorgan Chase & Co | 10 | $27 | 0.00% | +1+11.1% | Added |
| Royal Bank of Canada | 51 | $0 | 0.00% | +13+34.2% | Added |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −25,253−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −144−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −62−100.0% | Sold out |